<scp>TRPS1</scp> outperforms <scp>GATA3</scp> in pleural effusions with metastatic breast carcinoma versus mesothelioma

Baban, Farah; Koepplin, Justin W.; Ahmad, M.; Clarke-Brodber, Anna-Lee; Bois, Melanie C.; Hartley, Christopher; Sturgis, Charles D.

doi:10.1002/dc.25148

Cited by 5 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data confirm the recently proposed utility of the combination TRPS1 and GATA3 IHC for the assessment of tumor masses of unknown origin 10 , 26 , 27 and for the distinction of breast cancer from other specific tumor entities. 51 – 53 A major advantage of this combination lies in the virtual absence of TRPS1 positivity in urothelial carcinomas, the tumor entity with the second highest GATA3 positivity rate after breast cancer. In our analysis, a combined GATA3 and TRPS1 positivity was almost exclusively seen in neoplasms of the breast and the salivary glands.…”

Section: Discussionmentioning

confidence: 99%

TRPS1 is a Highly Sensitive Marker for Breast Cancer

Lennartz,

Löhr,

Höflmayer

et al. 2024

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Trichorhinophalangeal syndrome 1 (TRPS1) is a nuclear protein highly expressed in breast epithelial cells. TRPS1 immunohistochemistry (IHC) has been suggested as a breast cancer marker. To determine the diagnostic and prognostic utility of TRPS1 IHC, tissue microarrays containing 19,201 samples from 152 different tumor types and subtypes were analyzed. GATA3 IHC was performed in a previous study. TRPS1 staining was seen in 86 of 152 tumor categories with 36 containing at least one strongly positive case. TRPS1 staining predominated in various types of breast carcinomas (51%-100%), soft tissue tumors (up to 100%), salivary gland tumors (up to 46%), squamous cell carcinomas (up to 35%), and gynecological cancers (up to 40%). TRPS1 positivity occurred in 1.8% of 1083 urothelial neoplasms. In invasive breast carcinoma of no special type, low TRPS1 expression was linked to high grade (P= 0.0547), high pT (P< 0.0001), nodal metastasis (P= 0.0571), loss of estrogen receptor and progesterone receptor expression (P< 0.0001 each), and triple-negative status (P< 0.0001) but was unrelated to patient survival (P= 0.8016). In squamous cell carcinomas from 11 different sites, low TRPS1 expression was unrelated to tumor phenotype. Positivity for both TRPS1 and GATA3 occurred in 47.4% to 100% of breast cancers, up to 30% of salivary gland tumors, and 29 (0.3%) of 9835 tumors from 134 other cancer entities. TRPS1 IHC has high utility for the identification of cancers of breast (or salivary gland) origin, especially in combination with GATA3. The virtual absence of TRPS1 positivity in urothelial neoplasms is useful for the distinction of GATA3-positive urothelial carcinoma from breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

TRPS1 is a Highly Sensitive Marker for Breast Cancer

Lennartz,

Löhr,

Höflmayer

et al. 2024

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

Trichorhinophalangeal syndrome 1 expression in breast and nonbreast metastases from Müllerian, lung, gastrointestinal tract, and pancreatic primary tumors by immunohistochemistry with cytology cell block specimens

Donthi,

Gan,

Ding

et al. 2024

Cancer Cytopathology

View full text Add to dashboard Cite

BackgroundTrichorhinophalangeal syndrome 1 (TRPS1) expression in primary breast and other solid tumors has been investigated but its role as a marker in metastatic tumors is unclear. The objective of this study was to evaluate the sensitivity and specificity of TRPS1 as a breast cancer immunomarker in metastatic tumors that originated from breast, Müllerian, lung, gastrointestinal (GI), and pancreatic primary tumors with cell blocks from fine‐needle aspiration (FNA) and effusion specimens.MethodsCell blocks were immunostained with anti‐TRPS1 monoclonal antibody (clone EPR16171). Histochemical scores (H scores) (proportion × intensity; range, 0–300) were assigned; H scores of ≥10 were considered positive. Overall, 160 specimens were examined, including 127 FNAs (35 breast, 25 Müllerian, 36 lung, and 31 GI and pancreatic carcinomas) and 33 effusion specimens (18 breast, 12 Müllerian, one lung, and two GI carcinomas).ResultsTRPS1 was positive in 51 of 53 (96%) metastatic breast carcinomas and in 28 of 107 (26.2%) nonbreast metastatic tumors. Metastatic breast carcinoma showed the highest mean H score of 247.35, compared to 45.36 in Müllerian, 8.4 in lung, and 5.88 in GI tumors. The sensitivity and specificity of TRPS1 for identifying a breast origin in metastatic tumors was 96.22% and 72.89%, respectively.ConclusionsDespite high overall sensitivity, TRPS1 showed lower specificity as a breast immunomarker because of its expression in nonbreast tumors. The mean H score in nonbreast tumors was significantly lower than in metastatic breast tumors. It is important to recognize the broad range of expression of TRPS1 in metastatic breast and nonbreast tumors to avoid an incorrect determination of a metastatic tumor’s organ of origin.

show abstract

Effect of decalcification on immunohistochemical staining of trichorhinophalangeal syndrome type 1

Miao,

Chen,

Han

et al. 2024

Precision Medical Sciences

View full text Add to dashboard Cite

To evaluate the effect of different decalcification solutions on the immunohistochemical staining of trichorhinophalangeal syndrome type 1 (TRPS1), and to provide a reliable basis for the accurate diagnosis of bone metastasis of breast cancer. Due to the limited biopsy samples of bone metastatic cancer, 20 cases of invasive breast cancer were selected to simulate bone metastatic biopsy, dividing into four groups: undecalcified group, 30% formic acid group, 10% hydrochloric acid group and 10% nitric acid group. Immunohistochemical staining was performed after treatment for 2, 6, 18 and 24 h. There was no change in the proportion and intensity of TRPS1 cells in the formic acid decalcification group within 18 h, but decreased significantly after 24 h. The staining intensity of TRPS1 and the proportion of stained cells were significantly decreased in the hydrochloric acid decalcification group since 2 h treatment. The percentage and intensity of positive cells in the nitric acid decalcification group changed little or no change within 6 h, and then gradually decreased with the extension of time. Another three invasive breast cancer samples were used to compare the effects of different decalcification solutions on the same case. In brief, we conclude that the effect of 30% formic acid decalcification on TRPS1 staining is small when the time is less than 18 h. 10% nitric acid decalcification should be controlled within 6 h, which has little effect on TRPS1 staining, and 10% hydrochloric acid decalcification will lead to significantly less positive TRPS1 staining, so it is not recommended for breast bone metastasis tissue decalcification.

show abstract

TRPS1 outperforms GATA3 in pleural effusions with metastatic breast carcinoma versus mesothelioma

Cited by 5 publications

References 31 publications

TRPS1 is a Highly Sensitive Marker for Breast Cancer

TRPS1 is a Highly Sensitive Marker for Breast Cancer

Trichorhinophalangeal syndrome 1 expression in breast and nonbreast metastases from Müllerian, lung, gastrointestinal tract, and pancreatic primary tumors by immunohistochemistry with cytology cell block specimens

Effect of decalcification on immunohistochemical staining of trichorhinophalangeal syndrome type 1

Contact Info

Product

Resources

About